Personally, I am long-term bullish for $UnitedHealth(UNH)$ but for short to mid term, it is not as interesting as compared to AI stocks. It suits investors with a lot of patience and who love steady return.
UnitedHealth is an American multinational health insurance and services company. Selling insurance products under UnitedHealthcare, and health care services and care delivery aided by technology and data under Optum, it is the world's eleventh-largest company by revenue and the largest health care company by revenue.
A key reason UnitedHealth Group could get to a $1 trillion market cap is the company's relentless pursuit of growth. UnitedHealth's broad business involves not just health insurance, but analytics as well. And the company hasn't been afraid to get bigger and diversify via acquisitions.
In the fourth quarter, the company's medical loss ratio increased to 85%, higher than analysts expected. Medical loss ratio, or the percentage of premiums the company pays out to cover claims, is a key indicator of profitability for a company like UnitedHealth. The higher the medical loss ratio, the less room the company has to make a profit.
Hope this analysis helps.
@TigerPicks @Tiger_comments @MillionaireTiger @TigerStars @CaptainTiger @Daily_Discussion @TigerGPT
Will $UNH's Q1 Earnings Serve as the Catalyst for Stock Rebound?
@TigerPicks：
It was a rough week for the stock market, with Fed officials casting doubts on rate cuts and chip stocks failing to live up to expectations. The best-performing concepts are managed health care, marine ports and airlines concept. Considering the different perceptions of the stock, this time TigerPicks chose $UnitedHealth(UNH)$ to have a fundamental highlight to help users understand it better. $UnitedHealth(UNH)$ UnitedHealth Group's first-quarter report beat expectations, providing relief to investors. The healthcare powerhouse has faced challenges such as regulatory scrutiny and a cyber attack, but remains a strong business with exceptional growth opportunities. The stock has historically experienced sharp rises following periods of underperformance, and its current valuation suggests potential for market-beating returns. Being An Important Healthcare Company Is A Double-Edged Sword Many people are frustrated with the United States' healthcare system. From complex market structures in pharma to unclear insurance benefits and high medical costs, it's hard for an individual to navigate. While many blame UNH for being part of the problem, I believe that at the end of the day, without companies like UNH, the situation would be severely worse. The company has the largest number of members under its insurance arm, one of the largest physician networks, and plenty of other businesses that are irreplaceable in the healthcare value chain. Being such an integral part of the U.S. healthcare system is a double-edged sword. On the one hand, this is a market with unparalleled resiliency and an extremely strong secular growth trend. On the other hand, the regulator is constantly watching over everything you do, and politicians look for easy gains at your expense. This means that more often than not, you'll see a negative headline regarding UNH, or one of its businesses. Whether it's PBM investigations, bearish CMS reforms, or just worse-than-expected flu seasons, there's always something to worry about. During gloomy times, it's important to remember that healthcare is one of the only categories that consistently gains more share of GDP, and UNH is very well positioned to capitalize on this trend. Historically, The Stock Experiences Sharp Rises Following Extended Underperformance UnitedHealth has quite an ambitious EPS growth target of 13%-16%. There are many doubters, but the company continues to silence them, with a 15.8% 10-year CAGR, 14.4% 5-year CAGR, and 14.2% 3-year CAGR. The reason the company can achieve such extraordinary growth rates is due to the secular growth trends we discussed above, combined with its unparalleled presence across the value chain. Moreover, UNH is a cash printer, with cash conversion rates that are always higher than 1x. This allows UNH to buy back shares at a rapid pace while providing a fast-growing dividend. Here's a not-so-bold take. If UNH meets even the low end of its target range over the next decade, or even if it comes a bit below, the stock will provide market-beating returns. When the S&P average is mid-single-digits, the path to beat it is clear. However, there are periods, sometimes extended periods, when the negative headlines overshadow the underlying fundamentals, and put significant pressure on the stock. 图表 We can see that between 2015 and H1-16, the stock trod water, while the S&P was up. This period was followed by a very sharp upswing, which lasted between H2-16 and 2019 with almost no interruptions. Then, another long year of underperformance came, which was again followed by a remarkable 2.5-year period of a sharp rise. Today, we're standing somewhere above the bottom of a two-year stretch of stagnation and a selloff. Once again, it's mostly a result of a convergence between several temporary headwinds. In my view, we're at the cusp of the next upswing, and there are plenty of fundamental reasons to back that up. Valuation & The Makings Of The Next Upswing Despite the extremely negative backdrop, UnitedHealth was able to achieve 8.5% revenue growth, and 10.3% adjusted EPS growth, which could have been even higher if they excluded business disruption impacts from the cyber attack. Furthermore, unlike what many investors expected, UNH reaffirmed its 2024 adj. EPS guidance range of $27.5-$28.0 (which excludes direct impacts from the cyber attack, amortization, and a loss on sale of a subsidiary, but includes business disruption impacts). Essentially, UNH upgraded its guidance, while other companies in the sector have already lowered their guidance several times as they were unprepared for higher utilization, mispriced their benefit plans, and are struggling to generate internal cost savings to offset their mistakes. The company also reiterated its long-term growth targets, and sounded much less worried about the CMS final rate, unlike its frustrated competitors. This is a clear testament to UnitedHealth Group's unparalleled strength in the sector and a showcase as to why it receives a higher multiple than its peers. Chart Data by YCharts So, based on the reaffirmed guidance, which is in line with consensus estimates, UNH is trading at an 18.0x P/E. Remember, the EPS projections for the year are weighed down by direct business disruption caused by the cyber attack, and it's also important to understand that it took a lot of focus from management, which must have affected results indirectly in some way as well. On next year's projections, which are much more reflective, the stock is trading at 16x. Let's see where that puts us from a historical standpoint. Chart Data by YCharts As we can see, aside from a short period during COVID-19, an 18x P/E is the lowest level we've seen in the last decade, and the average is around 20x. With the company's underlying growth prospects and fundamentals unchanged, I place a price target of $550 for the end of 2024, which reflects a 20x P/E over this year's EPS, and an 18x P/E over 2025 earnings. In simple words, I expect UnitedHealth Group to recover back to its average valuation by the end of this year, as we get further away from the cyberattack, utilization trends normalize, and the overwhelming pessimism about the company fades. Conclusion To say UnitedHealth Group had a rough stretch would be an understatement. The company had to deal with multiple headwinds, which took a lot of management's focus and pressured the stock. Still, they managed to grow revenues at a high-single-digit pace and reaffirm their guidance, while competitors (who didn't have to manage a cyber attack) aren't able to achieve a similar feat. This speaks to the strength of UNH's unique company, and to the unparalleled quality of its management. I believe the first-quarter results provided enough confidence for investors to leave those headwinds behind and focus on the company's fundamentals, which remain intact. Stock Price Forecast: Here are the target price forecasts for the next 12 months from analysts. Based on 17 Wall Street analysts offering 12 month price targets for UnitedHealth in the last 3 months. The average price target is $591.29 with a high forecast of $675.00 and a low forecast of $480.00. The average price target represents a 17.99% change from the last price of $501.13. Resource: https://seekingalpha.com/article/4684477-unitedhealth-group-a-loud-sigh-of-relief-in-q124 What are your thoughts on $UnitedHealth(UNH)$? Or do you know other companies in the industry? Please leave your comment below. 🎁Prizes All Tigers who leave valid comments in the comments section will receive Tiger Coins.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
2
Report
Login to post
UnitedHealth Group (UNH) Stock Analysis
Business Overview: UnitedHealth Group is an American multinational health insurance and services company. It sells insurance products under UnitedHealthcare and provides health care services and care delivery aided by technology and data under Optum. It is the world's eleventh-largest company by revenue and the largest health care company by revenue.
Earnings Analysis: The latest earnings report for UnitedHealth Group shows that in Q1 2024, the company reported an EPS of -1.53 USD, with a gross profit margin of 23.05%. The return on investment was 11.77%, and the net profit margin was -1.41%. These figures indicate some challenges in the recent quarter.
Looking at the earnings forecast, analysts predict that UnitedHealth Group's EPS will be 27.60 USD for FY2024, 31.07 USD for FY2025, and 35.03 USD for FY2026. The forecasted gross income is 397.86B USD for FY2024, 427.24B USD for FY2025, and 456.78B USD for FY2026. The forecasted EBIT is 36.67B USD for FY2024, 39.38B USD for FY2025, and 42.52B USD for FY2026.
Trend Analysis: The current stock price of UnitedHealth Group is 494.43 USD (as of 2024-04-22). The support price on 2024-04-19 was 487.98 USD, and the resistance price was 501.18 USD. The average cost on 2024-04-19 was 485.79 USD. The profiteer ratio on 2024-04-19 was 0.7841.
Valuation Analysis: Analysts have provided target price estimates for UnitedHealth Group. The mean target price is 569.32 USD, with a low estimate of 460.00 USD and a high estimate of 675.00 USD. Additionally, 9 analysts recommend buying the stock, 16 analysts rate it as a buy, and 3 analysts suggest holding the stock.
Capital Flow Analysis: The capital flow data for UnitedHealth Group shows that there has been a mix of inflows and outflows in the past five days. On 2024-04-15, there was an inflow of 20,117.49K units, followed by an inflow of 100,459.4K units on 2024-04-16. On 2024-04-17, there was an inflow of 54,231.31K units, and on 2024-04-18, there was an inflow of 41,425.49K units. On 2024-04-19, there was a significant inflow of 119,887.03K units.
Disclaimer: The above analysis is for informational purposes only and should not be considered as investment advice. Investing in stocks involves risks, and stock prices can fluctuate. It is essential to conduct thorough research and analysis before making any investment decisions.